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ABSTRACT
Tolvaptan is a vasopressin V2-receptor antagonist that has shown promise in treating Autosomal Dominant Polycystic
Kidney Disease (ADPKD). Tolvaptan was, however, associated with liver injury in some ADPKD patients. Inhibition of bile
acid transporters may be contributing factors to drug-induced liver injury. In this study, the ability of tolvaptan and two
metabolites, DM-4103 and DM-4107, to inhibit human hepatic transporters (NTCP, BSEP, MRP2, MRP3, and MRP4) and bile
acid transport in sandwich-cultured human hepatocytes (SCHH) was explored. IC50 values were determined for tolvaptan,
DM-4103 and DM-4107 inhibition of NTCP (41.5, 16.3, and 95.6lM, respectively), BSEP (31.6, 4.15, and 119lM, respectively),
MRP2 (>50, 51.0, and >200lM, respectively), MRP3 (>50, 44.6, and 61.2lM, respectively), and MRP4 (>50, 4.26, and
37.9lM, respectively). At the therapeutic dose of tolvaptan (90 mg), DM-4103 exhibited a Cmax/IC50 value >0.1 for NTCP,
BSEP, MRP2, MRP3, and MRP4. Tolvaptan accumulation in SCHH was extensive and not sodium-dependent; intracellular
concentrations were 500lM after a 10-min incubation duration with tolvaptan (15lM). The biliary clearance of taurocholic
acid (TCA) decreased by 43% when SCHH were co-incubated with tolvaptan (15lM) and TCA (2.5lM). When tolvaptan
(15lM) was co-incubated with 2.5lM of chenodeoxycholic acid, taurochenodeoxycholic acid, or glycochenodeoxycholic acid
in separate studies, the cellular accumulation of these bile acids increased by 1.30-, 1.68-, and 2.16-fold, respectively. Based
on these data, inhibition of hepatic bile acid transport may be one of the biological mechanisms underlying tolvaptan-
associated liver injury in patients with ADPKD.
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Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a
monogenic inheritable disease characterized by progressive re-
nal cyst development, often leading to end-stage-renal-disease.
Supportive care and surgical interventions represent the main-
stay of ADPKD treatment because no Food and Drug
Administration (FDA)-approved therapy currently exists (Patel
et al., 2014; Torres et al., 2007). Tolvaptan, an orally available
benzazepine derivative, is a selective vasopressin V2-receptor
antagonist (Yamamura et al., 1998) used in the treatment of clin-
ically significant hyponatremia (Schrier et al., 2006), volume
overload in heart failure (Fukunami et al., 2011) and liver cirrho-
sis with edema (Sakaida, 2014). Tolvaptan recently has shown
VC The Author 2015. Published by Oxford University Press on behalf of the Society of Toxicology.
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promise for delaying renal cyst progression in ADPKD (Boertien
et al., 2015; Higashihara et al., 2011; Torres et al., 2012) with ap-
provals in Canada and Europe for this indication. In the pivotal
clinical trial, however, tolvaptan was associated with liver in-
jury evident as increased liver enzymes and bilirubin in some
patients. No signals of liver injury have been observed in patient
populations treated with tolvaptan for other indications or in
nonclinical studies (Oi et al., 2011; Watkins et al., 2015). The etiol-
ogy and/or biological mechanism(s) underlying tolvaptan-
associated liver injury in patients with ADPKD have yet to be
elucidated.
Drug-induced liver injury (DILI) is a frequent safety concern
during drug development that has led to prescribing restrictions
for some drugs (eg, trovafloxacin) and market withdrawal for
others (eg, troglitazone) (Senior, 2014). Cholestatic and hepato-
cellular liver injury are 2 major forms of DILI, but despite exten-
sive research, the underlying pathophysiological mechanism(s)
remain ill-defined and are likely compound-specific. Inhibition
of bile acid transport is one mechanism of DILI leading to intra-
cellular accumulation of hydrophobic bile acids that can cause
necrotic and/or apoptotic cell death (Marion et al., 2007; Perez
and Briz, 2009; Wagner et al., 2009). The major transport proteins
responsible for the basolateral uptake and biliary excretion of
bile acids in humans are Naþ-taurocholate cotransporting poly-
peptide (NTCP/SLC10A1) and the bile salt export pump (BSEP/
ABCB11), respectively. Inhibition of BSEP-mediated bile acid
transport has been implicated in DILI (Morgan et al., 2010;
Woodhead et al., 2014). In addition, multidrug resistance-
associated proteins 2, 3, and 4 (MRP2/ABCC2, MRP3/ABCC3, and
MRP4/ABCC4) also transport bile acids and may represent com-
pensatory pathways for hepatic bile acid excretion under duress
(Akita et al., 2002; Rius et al., 2006; Zelcer et al., 2003). Recently,
our group demonstrated that inhibition of MRP4, in addition to
BSEP, may be a risk factor for the development of cholestatic
DILI (Ko¨ck et al., 2014). Despite the association between bile acid
inhibition and DILI, not all bile acid inhibitors cause DILI, sug-
gesting that other mechanism(s) or patient-specific susceptibil-
ity factors may play a role in the development of DILI (Morgan
et al., 2013).
In humans, tolvaptan exhibits dose-linear pharmacokinetics
with an apparent elimination half-life ranging from 3 h to 12 h
depending on the dose (Kim et al. 2011; Shoaf et al. 2007) and an
oral bioavailability of 50% following a 30-mg dose (Shoaf et al.,
2012a). Tolvaptan is eliminated primarily by extensive CYP3A
metabolism (Shoaf et al., 2012b) with several metabolites detect-
able in the plasma including an oxybutyric acid metabolite (DM-
4103) and a hydroxybutyric acid metabolite (DM-4107) (Figure 1;
Sorbera et al., 2002; Tammara et al., 1999). DM-4103 has a long
half-life (180 h) in humans. Following a single, 60-mg oral dose
of 14C-tolvaptan, plasma concentrations of DM-4103 are mea-
surable for as long as 456 h and account for 52% of plasma ra-
dioactivity. While circulating concentrations of DM-4107 are
lower than tolvaptan (which represents <3% of plasma radioac-
tivity), 20% of a tolvaptan dose is excreted in urine and feces
as this metabolite (Sorbera et al., 2002; Tammara et al., 1999). In
addition to the unknown etiology of tolvaptan-associated liver
injury in ADPKD patients, it is also unclear whether DILI ob-
served in ADPKD patients is due to the parent compound, a me-
tabolite of tolvaptan, or some other specie(s).
These studies were designed to elucidate the interaction of
tolvaptan and 2 metabolites, DM-4103 and DM-4107, with sev-
eral proteins involved in the hepatic transport of bile acids. In
addition, the accumulation and vectorial transport of selected
bile acids in the absence and presence of tolvaptan was
examined in sandwich-cultured human hepatocytes (SCHH).
The results of this investigation, in combination with other on-
going research examining alternative potential mechanisms of
hepatotoxicity (eg, mitochondrial toxicity, adaptive immune
response), may provide important information to aid in deter-
mining the mechanism(s) underlying liver injury in tolvaptan-
treated ADPKD patients.
MATERIALS ANDMETHODS
Materials
[3H]Taurocholic acid (TCA, 15.4 Ci/mmol), [3H]estradiol-17b-
glucuronide (E217G, 41.4 Ci/mmol), and [
3H]dehydroepiandrost
erone sulfate (DHEAS, 60 Ci/mmol) were purchased from
PerkinElmer (Schwerzenbach, Switzerland). Unlabeled substrates
(TCA, E217G, and DHEAS) were purchased from Cayman
Chemicals (Ann Arbor, Michigan) or Sigma-Aldrich (St. Louis,
Missouri). Stable-labeled TCA (d8-TCA) and chenodeoxycholic
acid (d5-CDCA) were purchased from Martex Inc. (Minnetonka,
Minnesota). Glycochenodeoxycholic acid (GCDCA), taurocheno-
deoxycholic acid (TCDCA), and erythromycin-estolate were pur-
chased from Sigma-Aldrich. MK-571 was purchased from
Cayman Chemicals. A/E Type glass filters (25 mm) used in mem-
brane vesicle studies were purchased from Pall Life Sciences
(Ann Arbor, Michigan). Supplements added to culture NTCP-CHO
cells were purchased from Invitrogen (Zug, Switzerland).
Tolvaptan, DM-4103, and DM-4107 were provided by Otsuka
Pharmaceutical Co. Ltd (Tokyo, Japan). The purity of these com-
pounds was >99%.
Cell Culture
Chinese hamster ovary (CHO) cells. CHO cells expressing human
NTCP seeded in a 96-well format were obtained from Solvo
Biotechnology (Szeged, Hungary). Cells were stored in a
humidity-controlled incubator (37C, 5% CO2) until used. If pos-
sible, studies were completed on the day CHO cells arrived. In
the event that experiments were not conducted on the arrival
day, the media was replaced according to the supplier’s protocol
and the experiment was conducted within 24 h.
Sandwich-cultured human hepatocytes. SCHH were prepared by
Qualyst Transporter Solutions (Durham, North Carolina) using
Transporter Certified cryopreserved human hepatocytes from
donor S-1099 (Kaly-Cell, Plobsheim, France) or donor HUM4059
(Triangle Research Laboratories, Durham, North Carolina).
Cryopreserved hepatocytes were thawed following the suppli-
er’s thawing instructions. SCHH were prepared by plating hepa-
tocytes suspended in propriety hepatocyte QualGro Seeding
Medium (Qualyst Transporter Solutions) at a density of 0.7  106
viable cells/ml onto BioCoat 24-well cell culture plates (BD
Biosciences, San Jose, California). Following plating, cells were
allowed to attach for 2–4 h, rinsed and fed with warm (37C)
seeding medium. Eighteen to 24 h later, cells were fed and over-
laid with the appropriate species-specific proprietary culture
medium (Qualyst Transporter Solutions) supplemented with
the extracellular matrix Matrigel (BD Biosciences). Cells were
maintained in culture medium in a humidity-controlled incuba-
tor (37C, 5% CO2) until experiments were conducted on day 5 of
culture.
Assays
Membrane vesicle assay. BSEP, MRP2, and MRP4 membrane
vesicles were obtained from GenoMembrane (Kanagawa, Japan)
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and MRP3 membrane vesicles were obtained from Solvo
Biotechnology. Membrane vesicles (10 mg BSEP, 5 mg MRP2, 10 mg
MRP3, 5 mg MRP4, or control vesicles) were incubated at 37C
with the substrate [3H]TCA, [3H]E217G, or [
3H]DHEAS (2 mCi/ml)
supplemented with the unlabeled substrate to achieve a con-
centration of 2 mM TCA (for BSEP), 50 mM E217G (for MRP2), 10 mM
E217G (for MRP3), or 2 mM DHEAS (for MRP4) in transport buffer
(10 mM Hepes-Tris for BSEP; 40 mM MOPS-Tris for MRP2 and
MRP4; 10 mM Tris-HCl for MRP3) containing MgCl2 (10 mM),
sucrose (50 mM for BSEP or 250 mM for MRP3) and adenosine tri-
phosphate (ATP) or adenosine monophosphate (AMP) (4 mM) in
a final volume of 50 ml. Dimethyl sulfoxide (DMSO) was used to
solubilize tolvaptan, DM-4103, and DM-4107; the final concen-
tration of DMSO was <1% vol/vol. After incubation for 2 min (for
BSEP and MRP4), 3 min (for MRP2), or 5 min (for MRP3) with
vehicle or increasing concentrations of tolvaptan, DM-4103, or
DM-4107, the reaction was stopped by the addition of 800 ml ice-
cold transport buffer and immediately filtered using A/E glass
fiber filters presoaked in transport buffer overnight. The tested
concentrations and incubation time points were determined by
the limit of solubility for each compound and from preliminary
data (data not shown). For the BSEP uptake studies, the filters
were presoaked with 1 mM TCA solution to minimize nonspe-
cific binding. For the MRP2, MRP3, and MRP4 uptake studies, the
filters were presoaked with 3 mM reduced glutathione and
10 mM dithiothreitol solution to minimize nonspecific binding.
The filters were washed 3 times with ice-cold transport buffer
using a vacuum filtration system. The filters were transferred
to glass vials, and 10 ml liquid scintillation cocktail was added
and mixed by vortex before analysis using the Tri-Carb 3100
TR liquid scintillation analyzer (PerkinElmer, Waltham,
Massachusetts). The ATP-dependent uptake of substrate was
calculated by subtracting substrate uptake in the presence of
AMP from substrate uptake in the presence of ATP. The assays
were performed in triplicate in 3 separate experiments.
CHO transport studies. CHO cells were rinsed twice with 100 ml of
prewarmed (37C) Krebs-Henseleit uptake buffer with or
without Naþ. A third aliquot of 100 ml transport buffer was left
on the cells and incubated at 37C for 15 min. The media was
then aspirated and discarded. Uptake was initiated by the addi-
tion of prewarmed (37C) uptake buffer containing the substrate
[3H]TCA (2 mCi/ml) supplemented with unlabeled TCA to achieve
a concentration of 1 mM. Increasing concentrations of tolvaptan
(0–50 mM), DM-4103 (0–75mM), and DM-4107 (0–200 mM) were
added to the substrate solution; the highest concentrations
approached the limit of solubility for each compound. DMSO
was used to solubilize tolvaptan, DM-4103, and DM-4107; the
final concentration of DMSO was <1% vol/vol. The cells were
incubated for 5 min at 37C. Transport was stopped by quick
aspiration of the radiolabeled solution; the cells were rinsed
3 times with 100 ml of ice-cold uptake buffer to stop the reaction.
The cells were solubilized by adding 100 mL of 100 mM NaOH and
left at room temperature for 2 min; 80 ml of the cell suspension
was mixed with 5 ml scintillation fluid for radioactivity counting
using the Tri-Carb 3100 TR liquid scintillation analyzer
(PerkinElmer). NTCP-mediated uptake of TCA was calculated by
subtracting substrate uptake in the absence of sodium from
substrate uptake in the presence of sodium. The assays were
performed in 3 separate experiments in triplicate.
SCHH Studies
Time-, temperature-, and Na1-dependent uptake of tolvaptan in
SCHH. On day 5 of culture, media was aspirated and the SCHH
were rinsed with 0.5 ml/well of standard or Ca2þ-free Hank’s
balanced salt solution (HBSS). For Naþ-dependent uptake stud-
ies, Naþ-containing or Naþ-free (choline) HBSS buffers were
used instead. After the second rinse, HBSS buffers were aspi-
rated completely and SCHH were incubated with 0.5 ml of
standard or Ca2þ-free HBSS buffers for 10 min (or Naþ-
containing or Naþ-free HBSS buffers for the NTCP-mediated
uptake studies). After 10 min, HBSS buffers were aspirated and
then incubated with standard HBSS buffer containing tolvaptan
(15lM) at 37C for 5, 10, or 20 min, or 4C for 10 min. DMSO was
used to solubilize tolvaptan; the final concentration of DMSO
was 0.2% vol/vol. For the Naþ-dependent uptake studies,
FIG. 1. Chemical structures of tolvaptan, DM-4103, and DM-4107.
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tolvaptan was incubated at 37C for 10 min. A tolvaptan concen-
tration of 15 mM was selected because it was the highest concen-
tration in the linear range for tolvaptan uptake (data not
shown). After incubation, the HBSS buffer was aspirated from
all wells and rinsed 3 times with ice-cold standard HBSS buffer.
Plates were sealed and stored at 80C until analysis.
Hepatobiliary disposition of TCA, CDCA, TCDCA, and GCDCA in the
presence of tolvaptan. On day 7 of culture, culture media was aspi-
rated completely and SCHH were rinsed with 0.5 ml/well of
standard or Ca2þ-free HBSS buffers. After the second rinse,
HBSS buffers were aspirated completely and SCHH were incu-
bated with 0.5 ml of standard or Ca2þ-free HBSS buffers for
10 min. After 10 min, HBSS buffers were aspirated completely
and then incubated with the standard HBSS containing 2.5 mM
of the probe substrate (d8-TCA, d5-CDCA, TCDCA, or GCDCA)
with or without tolvaptan (15 mM) for 10 min. After incubation,
the incubation solutions were aspirated from all wells and
rinsed 3 times with ice-cold standard HBSS buffer. Plates were
sealed and stored at 80C until analysis.
Analysis of tolvaptan, DM-4103, and DM-4107 in SCHH and media by
liquid chromatography-tandem mass spectrometry (LC-MS/MS). A
volume of 500 ml of lysis solution [70:30 methanol:water (v:v)
containing 27.5 nM internal standard] was added to each well of
previously frozen 24-well plates containing study samples.
Plates were shaken for 15 min and the cell lysate solution was
transferred to a Whatman 96-well Unifilter 25 mm MBPP/0.45 mm
PP filter plate (Maidstone, England) stacked on a 96-well deep-
well plate. Lysate was filtered into the deepwell plate by centri-
fugation (2000 g for 5 min). The sample filtrate was evaporated
to dryness and the samples were reconstituted in 200 ml sample
diluent (70:30 methanol:water containing 0.1% formic acid) and
mixed for 15 min on a plate shaker. The reconstituted samples
were transferred to a 0.45 -mm filter plate (Millipore, Billerica,
Massachusetts) and filtered into a 96-well plate by centrifuga-
tion (2000 g for 2 min) and sealed with a silicone capmat prior
to LC-MS/MS analysis. Analytical controls for tolvaptan, DM-
4103, and DM-4107 were measured using standard curves.
Analytical standards were prepared over a range of concentra-
tions to deliver, with the addition of a 10 -ml volume per well,
the range of mass 0.5–5000 pmoles/well for tolvaptan, DM-4103,
and DM-4107. Cell lysates from SCHH were utilized for the gen-
eration of standard curves and related quality control (QC) sam-
ples. QC lysate samples were prepared at the lower limit of
quantitation (LLQ) and the upper limit of quantitation (ULQ).
These lysate controls were further processed as described
above. A binary HPLC system (Shimadzu, Columbia, Maryland)
composed of LC-10ADvp pumps, a CTO-10Avp oven, and an
HTC-96-well autosampler was used. The chromatographic col-
umn was a Hypersil Gold C18 (100 1.0 mm2, 3 mm) with match-
ing guard (5 mm) and pre-column filter (Thermo Scientific,
Bellefont, Pennsylvania). Column temperature was maintained
at 35C. A mobile phase gradient composed of A¼ 50% methanol
with 0.1% formic acid and B¼ 90% methanol with 0.01% formic
acid was used at a flow rate of 50 ml/min and a total run time of
10 min. All test compounds were chromatographically resolved.
The gradient profile was: initial 25% B for 2.0 min; from 2.0 to 5.0
min ramp to 100% B and hold for 0.9 min; step back to 25% B at
6.0 min and re-equilibrate for 4.0 min. An injection volume of
5 ml was used. Tandem mass spectrometry with positive ion
electrospray ionization was conducted with a Thermo Electron
TSQ Quantum Discovery MAX (Thermo Fisher, Waltham,
Massachusetts) with an Ion Max ESI source. The transitions
monitored (parent m/z > product m/z) at unit resolution for tol-
vaptan, the internal standard, DM-4103, and DM-4107 were
449.2> 252.0, 463.2> 266.0, 479.0> 252.0, and 481.0> 252.0,
respectively. The analytical run was typically conducted with a
standard curve at the beginning of the run. A ULQ QC and a LLQ
QC sample were placed in the middle of the run and at the end
of the run. Analyte and internal standard peak area responses
were determined for the standards, QC’s, and unknown sam-
ples, and the unknown and QC samples (pmoles/well) were cal-
culated utilizing the standard curve. Analytical run ruggedness
was evaluated based on percent accuracy of the back calculated
values for the standards and QC’s. Acceptance criteria for per-
cent accuracy of back calculated values were typically 15%–20%.
Analysis of TCA, CDCA, TCDCA, and GCDCA. Analysis of d8-TCA,
d5-CDCA, TCDCA, and GCDCA was performed using LC-MS/MS
as described previously (Marion et al., 2012). Assay acceptance
criteria were similar to those defined above. For the analysis of
TCDCA and GCDCA only, the relative amounts (no standard
curve) were determined by measuring the peak area ratios from
the unknown LC-MS/MS peak area and the area of the corre-
sponding internal standard. Relative changes were determined
for individual treatments.
Data Analysis and Statistics
Membrane vesicle and CHO cell assays. Transporter-mediated
uptake was normalized to vehicle control values (without inhib-
itor). IC50 values were determined by nonlinear regression tech-
niques using the following equation in GraphPad Prism 6 (San
Diego, California):
Y ¼ 100= 1þ 10 XLogIC50ð Þ
h i
;
where X represents the log concentration of inhibitor and Y rep-
resents the percentage of control activity. Data are reported as
the point estimate and 95% confidence interval (CI). If the inhib-
itor did not reduce substrate transport by >50% at the highest
tested concentration, nonlinear regression to estimate an IC50
value was not conducted. The type of inhibition and inhibition
constant (Ki) for BSEP-mediated TCA transporter was deter-
mined by fitting competitive, noncompetitive, and uncompeti-
tive models to the untransformed data by nonlinear regression
analysis using GraphPad Prism 6. The best-fit model was
assessed based on visual inspection of the observed versus pre-
dicted data and the Akaike Information Criteria (Akaike, 1974).
Equations used for each inhibition model were as follows:
Competitive :  ¼ Vmax  S
Km  1þ IKi
 
þ S
Noncompetitive :  ¼ Vmax  S
Km  1þ IKi
 
þ S 1þ IKi
 
Uncompetitive :  ¼ Vmax  S
Km þ S 1þ IKi
  ;
where S represents the concentration of TCA, I represents the
concentration of tolvaptan or DM-4103, m represents the rate of
TCA transport, Vmax represents the maximal rate of TCA trans-
port, Km represents the TCA concentration that yields one-half
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maximal TCA transport, and Ki represents the dissociation con-
stant for the BSEP-inhibitor complex. Data are from n¼ 3 inde-
pendent experiments in triplicate.
Sandwich-cultured hepatocyte studies. All mass values were nor-
malized to the mean protein (mg) content per well from
SCHH. Protein content was determined using the Pierce BCA
protein assay kit. Cellular accumulation determined in Ca2þ-
free HBSS buffer was assumed to represent the total mass of
analyte inside the hepatocyte at the end of the incubation
time period. Total accumulation determined in standard
HBSS buffer represents the total mass of compound taken up
and excreted (cells þ bile). The biliary excretion index (BEI)
was calculated according to the following equation (Liu et al.,
1999a):
BEIð%Þ ¼ AccumulationStandard HBSSAccumulationCa2þfree HBSS
AccumulationStandard HBSS
100
The in vitro biliary clearance (Clbiliary) was determined
using the following equation (Ghibellini et al. 2007; Liu et al.,
1999b) and was scaled to body weight using scaling factors
(Qualyst Transporter Solutions Technical Application
Bulletin, 2011).
Clbiliary ¼
AccumulationStandard HBSS AccumulationCa2þfree HBSS
time concentrationmedia
The biliary clearance for DM-4103 and DM-4107 could not be
determined because the metabolites were generated endoge-
nously. The intracellular concentration of each test compound
was calculated by dividing the mass of compound in cells by the
respective hepatocyte intracellular fluid volume for human
hepatocytes (7.69 ml/mg protein; Qualyst Transporter Solutions
Technical Application Bulletin, 2011). All calculations were per-
formed using Microsoft Excel (Redmond, Washington).
RESULTS
NTCP- and BSEP-Mediated TCA Transport
TCA was used as a substrate to study the interaction of tolvap-
tan, DM-4103, and DM-4107 with the basolateral uptake trans-
porter NTCP. TCDCA (100mM) was used as a positive control and
inhibited NTCP-mediated uptake by >98% (data not shown). The
estimated IC50 values for tolvaptan, DM-4103, and DM-4107 were
41.5, 16.3, and 95.6mM, respectively (Figs. 2A–C; Table 1). TCA
was used as a substrate to study the interaction of tolvaptan,
DM-4103, and DM-4107 with the canalicular efflux transporter
BSEP. Rifampicin (50mM) was used as a positive control and
inhibited BSEP-mediated uptake by >50% (data not shown;
Byrne et al., 2002). BSEP-mediated TCA uptake was reduced to
16.4% of control when incubated with 50mM tolvaptan; the esti-
mated IC50 value was 31.6mM (Figure 2D; Table 1). DM-4103
inhibited BSEP-mediated TCA uptake with an IC50 value of
4.15mM, while the IC50 value for DM-4107 was 119mM (Figs. 2E
FIG. 2. Effect of tolvaptan, DM-4103, and DM-4107 on NTCP-mediated transport or BSEP-mediated transport of TCA. NTCP-overexpressing cells were co-incubated
with tolvaptan (0–50 lM), DM-4103 (0–75 lM), or DM4107 (0–200 lM) and [3H]TCA (2 mCi/ml; 1 mM) for 5 min at 37C (A-C); BSEP vesicles were co-incubated with tol-
vaptan (0–50 lM), DM-4103 (0–75 lM), or DM4107 (0–200 lM) and [3H]TCA (2 mCi/ml; 2 mM) for 2 min at 37C (D-F). NTCP-mediated uptake of TCA was calculated by
subtracting substrate uptake in the absence of sodium from substrate uptake in the presence of sodium. BSEP-mediated transport was calculated by subtracting
TCA uptake in the presence of AMP from TCA uptake in the presence of ATP. Values are expressed as percentage of vehicle control; each value represents the
mean6SD from 3 independent experiments. The curve represents the best fit line using nonlinear regression techniques. See “Materials and Methods” section
for further details.
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and F). The Ki was estimated using nonlinear regression by
incubating BSEP membrane vesicles with TCA (2–30 lM)
and designated concentrations of tolvaptan (0–50 lM) or DM-
4103 (0–20 lM). A Ki for DM-4107 was not determined because
it was a less potent inhibitor of BSEP-mediated TCA transport
based on the estimated IC50 value compared with tolvaptan
and DM-4103. Nonlinear regression analysis of the data
revealed that tolvaptan was best described by a noncompeti-
tive inhibition model (Ki¼ 34.2 lM), while DM-4103 was best
described by a competitive inhibition model (Ki¼ 3.77 lM)
(Figure 3).
MRP2- and MRP3-Mediated E217G Transport, and MRP4-Mediated
DHEAS Transport
E217G and DHEAS were used as substrates to study the inter-
action of tolvaptan, DM-4103, and DM4107 with the efflux
transporters MRP2, MRP3, and MRP4. MK-571 (50 lM) was
used as a positive control and inhibited MRP2-, MRP3- and
MRP4-mediated transport by >95%, >50%, and >90%, respec-
tively (data not shown). If transporter-mediated uptake of a
probe substrate was not inhibited by >50%, nonlinear regres-
sion analysis was not conducted (Figs. 4C, D, and G). At the
highest concentration of tolvaptan, MRP2-mediated E217G
uptake was 115% of control, indicating that tolvaptan did not
inhibit MRP2 transport (Figure 4A). The estimated IC50 value
for DM-4103 was 51.0 mM (Figure 4B). The estimated IC50 val-
ues for DM-4103 and DM-4107 mediated MRP3 inhibition
were 44.6 and 61.2 mM, respectively (Figs. 4E and F; Table 1).
DHEAS was used as a substrate to study the interaction of tol-
vaptan, DM-4103 and DM4107 with the basolateral efflux
transporter MRP4. At the highest concentration of tolvaptan
(50 lM), MRP4-mediated DHEAS uptake was 88% of control,
indicating that tolvaptan had minimal impact on MRP4 trans-
port (Figure 4G). The estimated IC50 values for DM-4103 and
DM-4107 were 4.26 and 37.9 mM, respectively (Figs. 4H and I;
Table 1).
DM-4103 inhibited MRP2-mediated E217G uptake by >50%
only at the highest tested concentration (Figure 4B). Although a
curve was fit to these data to estimate an IC50 of 51.0 mM, cau-
tion must be exercised when interpreting this value. The limits
of solubility precluded testing higher concentrations of DM-
4103. Such was the case with MRP3-mediated inhibition by DM-
4103 as well as NTCP-mediated inhibition by tolvaptan (Figs. 2A
and 4E).
Time- and Temperature-Dependent Uptake of Tolvaptan in SCHH
SCHH were incubated with tolvaptan (15mM) for 5, 10, or 20 min
at 37C or for 10 min at 4C. Tolvaptan accumulated in SCHH
reaching a concentration of 500 mM after 10 min, assuming
that binding to the hepatocyte surface was negligible and that
accumulation represented the mass of tolvaptan in the cell.
Temperature-dependent uptake suggested that both active and
passive components are involved in tolvaptan uptake
(Figure 5A). The BEI for tolvaptan was <10%, indicating a low
potential for biliary excretion of tolvaptan. In separate SCHH
studies, formation of both DM-4103 and DM-4107 was observed
during a 10-min incubation with tolvaptan (15mM) at 37C
(Figure 5B); the mean total (boundþunbound) cellular
FIG. 3. Effect of tolvaptan and DM-4103 on BSEP-mediated transport of TCA. Uptake of TCA (2, 5, 10, 20, or 30mM) was determined in the presence of 0 mM (), 10mM (*),
25mM (~), or 50 mM (D) tolvaptan (A) or 0 mM (), 2 mM(*), 5 mM (~), or 20mM (D) of DM-4103 (B). TCA uptake was measured after an incubation of 2 min at 37C in the pres-
ence or absence of inhibitor. BSEP-mediated transport was calculated by subtracting TCA uptake in the presence of AMP from TCA uptake in the presence of ATP; each
value represents the mean6SD from 3 independent experiments. The curves represent the best fit model using nonlinear regression techniques. See “Materials and
Methods” section for further details.
TABLE 1. Inhibitory Potency of Tolvaptan, DM-4103, and DM-4107 on
Transporter-Mediated Uptake
Transporter Inhibitor IC50 (mM) 95% CI (mM) Cmax/IC50
NTCP Tolvaptan 41.5 26.0–66.3 0.03
DM-4103 16.3 11.1–24.0 0.96*
DM-4107 95.6 58.7–156 0.02
BSEP Tolvaptan 31.6 16.5–60.3 0.04
DM-4103 4.15 3.45–4.99 3.78*
DM-4107 119 86.2–163 0.02
MRP2 Tolvaptan >50 NC NC
DM-4103 51.0 32.0–81.3 0.31*
DM-4107 >200 NC NC
MRP3 Tolvaptan >50 NC NC
DM-4103 44.6 30.9–64.5 0.35*
DM-4107 61.2 51.5–72.8 0.04
MRP4 Tolvaptan >50 NC NC
DM-4103 4.26 3.32–5.47 3.69*
DM-4107 37.9 32.1–44.7 0.06
IC50 values were determined by nonlinear regression techniques as described
in “Materials and Methods” section; data are reported as the IC50 estimate
and 95% CI of n¼3 independent experiments in triplicate. Mean Cmax values
were determined in subjects following a 90-mg dose of tolvaptan (Watkins
et al., 2015).
CI: confidence interval; mean Cmax following a 90-mg dose in humans; NC: non-
calculable. In cases where substrate uptake was inhibited by >50% only at the
highest tested inhibitor concentration, the data were curve fit in the usual man-
ner, but the estimated IC50 value was designated as an approximation (). If the
inhibitor did not reduce substrate transport by >50% at the highest tested con-
centration, nonlinear regression to estimate an IC50 value was not conducted
and the value was reported as greater than the highest tested concentration.
*Cmax values were not determined in clinical trials, therefore, concentrations at
steady-state were used instead.
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concentrations of tolvaptan, DM-4103 and DM-4107 were 530,
1.71, and 35.6 lM, respectively.
Sodium-Dependent (NTCP) Uptake of Tolvaptan in SCHH
To determine the sodium-dependent uptake of tolvaptan in
SCHH, hepatocytes were incubated in the presence or absence
of sodium. The total accumulation of tolvaptan and the accu-
mulation of generated DM-4103 and DM-4107 were unaffected
by the absence of sodium (Table 2).
Hepatobiliary Disposition of TCA, CDCA, TCDCA, and GCDCA in the
Presence of Tolvaptan in SCHH
The effect of tolvaptan on the hepatobiliary disposition of
4 model bile acids (TCA, CDCA, TCDCA, and GCDCA) was eval-
uated in SCHH. When co-incubated with 15 mM tolvaptan, the
total accumulation of TCA was decreased by 32.6% and the BEI
was decreased by 15.7% compared to control (Table 3). The com-
bined effect of the inhibition of both uptake and efflux by tol-
vaptan decreased the biliary clearance of TCA by 43% compared
to control (Table 3; Figure 6A). In contrast to TCA, the cellular
accumulation of CDCA tended to increase by 1.3-fold relative to
control. Tolvaptan-mediated changes in the biliary clearance
and BEI of CDCA were decreased by 55% and 61%, respectively,
compared to control (Table 3). Erythromycin estolate (100 mM), a
broad-spectrum efflux transport inhibitor, was used as a posi-
tive control and had no effect on the total accumulation
(cellþbile) of CDCA, but inhibited the biliary excretion of CDCA
(data not shown). Similar to CDCA, tolvaptan had no effect on
the total accumulation of TCDCA or GCDCA, but did appear to
increase the cellular accumulation (cells) of TCDCA and GCDCA
by 1.68 - and 2.16-fold, respectively, compared with control
when co-incubated with tolvaptan (Table 3; Figure 6B).
FIG. 4. Effect of tolvaptan, DM-4103, and DM-4107 on MRP2-mediated transport of E217G, MRP3-mediated transport of E217G, and MRP4-mediated transport of DHEAS.
MRP2 (A–C), MRP3 (D–F), or MRP4 (G–I) vesicles were co-incubated with tolvaptan (0–50lM), DM-4103 (0–50 lM for MRP2 and MPR3, and 0–20 lM for MRP4), or DM-4107
(0–200lM) and [3H]E217G (2 mCi/ml; 50mM) (A–C) for 2 min, [
3H]E217G (2 mCi/ml; 10mM) (D–F) for 5 min, or [
3H]DHEAS (2 mCi/ml; 2 mM) (G–I) for 2 min at 37C. MRP-mediated
transport was calculated by subtracting substrate uptake in the presence of AMP from substrate uptake in the presence of ATP. Values are expressed as percentage of
vehicle control; each value represents the mean6SD from 3 independent experiments. If the inhibitor did not reduce substrate transport by >50% at the highest tested
concentration, nonlinear regression to estimate an IC50 value was not conducted. The curve represents the best fit line using nonlinear regression techniques. See
“Materials and Methods” section for further details.
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DISCUSSION
In this study, the inhibitory effect of tolvaptan, DM-4103, and
DM-4107 on human hepatic bile acid transporters was investi-
gated. This study was undertaken because tolvaptan was asso-
ciated with liver injury in some patients with ADPKD during
clinical investigation. Liver injury had not been reported previ-
ously for other patient populations, eg, patients treated for
hyponatremia, or cardiac and hepatic edema. In the ADPKD piv-
otal trial and the subsequent ongoing open-label safety study
(NCT01214421), 4.9% of patients treated with tolvaptan had ele-
vated alanine aminotransferase levels compared with 1.2% of
those receiving the placebo (Torres et al., 2012). Fewer patients
treated with tolvaptan than those receiving the placebo (0.9% vs
1.9%) had increased bilirubin levels. However, 2 cases of Hy’s
Law were observed in tolvaptan-treated ADPKD patients, while
no Hy’s Law cases were reported in placebo-treated patients
(Torres et al., 2012). A third case of Hy’s Law was observed in a
tolvaptan-treated ADPKD patient in an open-label follow on
trial (Watkins et al., 2015). Furthermore, these observations did
not appear to be associated with dose or exposure and generally
occurred after 3 months or more of treatment (Watkins et al.,
2015).
Idiosyncratic DILI is, by definition, a rare event. There was
no apparent correlation between renal impairment, apparent
hepatorenal cyst burden or stage of ADPKD and occurrence of
hepatic events. Because of the low number of events, a defini-
tive conclusion about an association between cyst burden and
DILI cannot be made at this time. These data were described at
the FDA Advisory Committee meeting for tolvaptan (August
2013; www.fda.gov) but have not been published yet.
Interestingly, systemic tolvaptan exposure based on AUC
was greater in patients with reduced creatinine clearance
FIG. 5. Time- and temperature-dependent accumulation of tolvaptan in SCHH. Accumulation of tolvaptan in cellsþbile (black bars) and cells (white bars) was
measured by incubating SCHH with 15mM of tolvaptan for 5, 10, or 20 min at 37C, or for 10 min at 4C (A). Accumulation of tolvaptan, and the generated metabolites
DM-4103 and DM-4107 in cellsþbile (black bars) and cells (white bars) was measured by incubating SCHH with 15 mM of tolvaptan for 10 min at 37C (B). *Cellular con-
centrations were calculated using the total mass of tolvaptan, DM-4103, or DM-4107 in cells (white bars) and hepatocyte fluid volume as described in “Materials and
Methods” section; each value represents the mean6SD from n¼1 liver in triplicate.
TABLE 2. Sodium-Dependent Uptake of Tolvaptan, DM-4103 and DM-4107 in SCHH
Tolvaptan dose concentration Buffer Tolvaptan DM-4103 DM-4107
Total accumulation (pmol/mg) Total accumulation (pmol/mg) Total accumulation (pmol/mg)
15 mM Sodium 27306 397 7.826 0.84 1216 19
Choline 34606 684 8.356 0.83 1366 16
Accumulation of tolvaptan, DM-4103, and DM-4107 was measured by incubating SCHH with 15 mM of tolvaptan for 10 min in the presence or absence of sodium, as
described in “Materials and Methods” section. Data are presented as mean6SD (n¼1 liver in triplicate).
TABLE 3. Hepatobiliary Disposition of 2.5 mM TCA, Chenodeoxytaurocholic acid (CDCA), TCDCA or GCDCA in the absence or presence of tolvap-
tan (15mM) in SCHH
Probe Inhibitor Total accumulationa Cellular accumulationa Clbiliary (ml/min/kg) BEI (%)
TCA Vehicle control 2156 27 43.36 4.4 20.3 79.8
Tolvaptan 1456 16 47.56 2.1 11.6 67.3
CDCA Vehicle control 5806 67 469660 13.1 19.1
Tolvaptan 6586 86 608631 5.86 7.52
TCDCA Vehicle control 3.376 0.55 0.5456 0.049 NC 83.8
Tolvaptan 3.326 0.27 0.9156 0.22 NC 71.0
GCDCA Vehicle control 8.826 0.98 0.8926 0.065 NC 89.2
Tolvaptan 7.556 1.28 1.936 0.28 NC 74.5
aAccumulation of TCA, CDCA, TCDCA, or GCDCA was measured by incubating SCHH with or without 15mM of tolvaptan for 10 min in standard (total accumulation) or
Ca2þ-free (cellular accumulation) HBSS, as described in Materials and Methods. Data are presented as mean6SD (n¼1 liver in triplicate). Accumulation of TCA and
CDCA is expressed as pmol/mg protein; accumulation of TCDCA and GCDCA is expressed as peak area ratio; BEI¼biliary excretion index; NC: non-calculable.
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(<30 ml/min) than in patients with preserved renal function
(Shoaf et al., 2014). Thus, prolonged renal impairment may alter
excretory mechanisms thereby placing a larger burden on the
liver. With renal impairment in this population, an increase in
systemic exposure does occur compared with non-ADPKD
patients, although the differences are minimal since patients
with severe renal impairment were excluded from the pivotal
clinical trial (Torres et al., 2012). It is worth noting, however, that
the liver is the primary elimination pathway for tolvaptan/
metabolites (metabolism and fecal excretion) and not urinary
excretion (Shoaf et al., 2012a). Hence, increasing the hepatic bur-
den could alter hepatic exposure to tolvaptan/metabolites and
may be associated with bile acid transporter inhibition, as
shown in the present experiments.
BSEP inhibition has been implicated as one mechanism of
DILI, although inhibition of other efflux transporters such as
MRP2 and MRP4 also have been shown to exhibit an association
with DILI (Ko¨ck et al., 2014; Mennone et al., 2006; Morgan et al.,
2013). Under normal physiological conditions in humans, bile
acids, primarily the conjugated bile acids taurodeoxycholic acid
(TDCA), glycodeoxycholic acid (GDCA), TCDCA, and GCDCA, are
transported across the canalicular membrane into bile and
stored in the gallbladder until released into the duodenum
(Hofmann and Hagey, 2008; Rodrigues et al., 2014). Bile acids
concentrate in the bile ducts relative to hepatocytes; active
canalicular transport via BSEP is the rate-limiting step in bile
acid transport and an important determinant of bile flow
(Kullak-Ublick et al., 2004; Meier and Stieger, 2002). Inhibition of
BSEP may lead to accumulation of bile acids within hepatocytes
and subsequently induce cytotoxicity.
Cholestatic DILI is a subset of liver disease that can result
from direct damage to hepatic parenchyma (eg, hepatocytes,
bile ducts) through toxic or immunogenic mechanisms, and/or
by impairment of biliary excretory function. Apart from genetic
defects (eg, progressive familial intrahepatic cholestasis type 2),
numerous drugs have been implicated in cholestasis (Padda
et al., 2011). Cyclosporine, a prototypical drug that can induce
cholestatic liver injury, alters bile acid transport function, intra-
hepatic vesicle transport, canalicular membrane fluidity, and
bile-acid independent bile flow (Bo¨hme et al., 1994; Bramow
et al., 2001; Roma´n et al., 2003; Yasumiba et al., 2001). No cases of
hepatotoxicity were reported during the development of trogli-
tazone. However, this thiazolidinedione was removed from the
market due to idiosyncratic liver injury. Subsequent studies,
after market withdrawal, revealed that troglitazone and the sul-
fate conjugate of troglitazone inhibit BSEP. Further, studies with
troglitazone revealed that cholestasis was more prevalent in
male rats presumably due to sex-dependent differences in the
toxic sulfate-conjugated species (Funk et al., 2001; Kostrubsky
et al., 2001). These examples highlight the potential multi-
mechanistic nature of DILI as well as the interplay between the
formation and excretion of drug metabolites.
These present experiments were designed to test the
hypothesis that bile acid transporter interference could be a
biologically plausible mechanism to explain DILI in tolvaptan-
treated patients with ADPKD. As shown, DM-4103 was a 7.5-
fold and a 29-fold more potent inhibitor of BSEP (IC50: 4.15 lM)
compared with tolvaptan and DM-4107, respectively, based on
IC50 data (Table 1). The ratio between the concentration at
steady state (Css) or maximal plasma concentration (Cmax) and
the inhibitory potency (IC50) is used commonly to understand
the relationship between drug or metabolite exposure and
inhibition (Morgan et al., 2013; Zhang, 2012). According to FDA
guidance, when the estimated [I]/Ki or [I]/IC50 ratio is >0.1,
where [I] represents the total (bound plus unbound) mean
steady-state Cmax after administration of the highest proposed
clinical dose, an in vivo drug interaction study may be warranted
(Huang et al., 2008). For BSEP, both tolvaptan and DM-4107
exhibited (total) Cmax/IC50 values <0.1 while DM-4103 exhibited
a value of 3.78 (Table 1), which suggests that DM-4103 may be a
relevant inhibitor of BSEP at the therapeutic dose of 90 mg tol-
vaptan. However, cellular rather than plasma concentrations of
tolvaptan, DM-4103 and DM-4107 would be more relevant for
predictions of efflux inhibition.
To further understand BSEP inhibition, the mechanism of
inhibition was interrogated for tolvaptan and DM-4103.
Inhibition of BSEP by tolvaptan was best described by a non-
competitive inhibition model (Ki¼ 34.2 lM) while DM-4103 was
best described by a competitive inhibition model (Ki¼ 3.77 lM).
Unlike competitive inhibition, noncompetitive inhibition
reduces the rate of transport (eg, of bile acids) and the resulting
effects of depressed bile acid transport may lead to accumula-
tion of bile acids, impaired bile flow, and hepatotoxicity. This
principle is supported by Woodhead et al. (2014) who showed
that in a simulated patient population treated with CP-724,714,
an anti-cancer agent terminated from further development due
to hepatotoxicity thought to be due, in part, to BSEP inhibition
(Guo et al., 2008), clinically relevant ALT elevations developed
FIG. 6. Accumulation of TCA, CDCA, TCDCA, and GCDCA in the presence and absence of tolvaptan in SCHH. Accumulation of d8-TCA (2.5 mM) and d5-CDCA (2.5 mM) (A),
or TCDCA (2.5 mM) and GCDCA (2.5 mM) (B) in cellsþbile (black bars) and cells (white bars) was measured after incubating SCHH with designated bile acids in the pres-
ence or absence of tolvaptan (15 mM) for 10 min at 37C; each value represents the mean6SD from n¼1 liver in triplicate.
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more frequently when BSEP inhibition was noncompetitive in
nature. Mitochondrial toxicity also was implicated as a mecha-
nism of CP-724,714 toxicity (Feng et al., 2013) and clinical find-
ings suggest that CP-724,714 exerted both hepatocellular and
hepatobiliary cholestatic injury (Guo et al., 2008; Munster et al.,
2007).
As noted earlier, inhibition of BSEP alone cannot always pre-
dict or explain DILI. This may be due, in part, to the adaptive
abilities of the liver. When bile acids accumulate in hepatocytes,
compensatory or salvage pathways are transcriptionally upre-
gulated/downregulated that function as hepatoprotective
mechanisms (Wagner and Trauner, 2005). MRP4, a sinusoidal
bile acid efflux transporter, is normally expressed at low levels
in human hepatocytes but protein expression can be increased
significantly during cholestasis (Chai et al., 2012; Teng and
Piquette-Miller, 2007, Wagner et al., 2009; Zollner et al., 2006).
Alterations in other bile acid efflux transporter expression/func-
tion have been reported and include MRP2, MRP3 and organic
solute transporters (OSTa/OSTb), indicating a complex adaptive
response to cholestasis and/or bile acid-mediated toxicity
(Boyer et al., 2006; Trauner et al., 1997; Zollner et al., 2001).
Because of these potential adaptive responses, Morgan et al.
(2013) developed decision criteria for bile acid transporter-
mediated hazard identification, which includes evaluating the
inhibition of important bile acid efflux transporters (ie, MRP2,
MRP3, and MRP4) in addition to BSEP. All evaluated compounds
that exhibited a BSEP Css/IC50 ratio 0.1 and either a MRP2,
MRP3, or MRP4 Css/IC50 ratio 0.1 were associated with some
form of liver injury. These findings highlight the potential
importance of compensatory mechanisms of bile acid transport
when BSEP is impaired. Because inhibition of MRP-mediated
transport function, in addition to BSEP, is associated with DILI,
we sought to determine the inhibitory potency of tolvaptan,
DM-4103, and DM-4107 on MRP2-, MRP3-, and MRP4-mediated
transport function.
As shown, tolvaptan and DM-4107 showed no or marginal
MRP2 inhibition, respectively (Figs. 4A–C). Although DM-4103
inhibited MRP2-mediated transport by >50% at the highest
tested concentration, caution should be exercised when inter-
preting the IC50 of DM-4103 (51.0 lM) because limits of solubil-
ity precluded testing the effects of higher tolvaptan
concentrations on MRP2-mediated transport. Such was the case
with DM-4103 on MRP3-mediated transport. Tolvaptan showed
no effect on MRP3-mediated transport and although the IC50 for
DM-4107 was estimated to be 61.2 lM, the Cmax/IC50 value was
0.04, indicating that DM-4107 may not be a relevant inhibitor of
MRP3 (Table 1). In contrast, the Cmax/IC50 value for DM-4103 was
0.35 for MRP3-mediated transport. DM-4103 was an 9-fold
more potent inhibitor of MRP4-mediated transport based on
IC50 when compared with DM-4107 (IC50 of 4.26 vs 37.9 lM,
respectively), while tolvaptan exhibited minimal inhibition of
MRP4-mediated transport (Figs. 4G–I). When taking into account
plasma concentrations, DM-4103 exhibited a Cmax/IC50 value of
3.69 for MRP4 (Table 1), indicating that DM-4103 may be a rele-
vant inhibitor of the basolateral efflux transporter MRP4 since
this ratio was >0.1. The effects of tolvaptan on BSEP, MRP2, and
MRP4 transport were similar to the IC50 values reported by
Morgan et al. (2013) (9.99,> 133, and>133 lM, respectively).
Although over-expressing cell lines and inside-out mem-
brane vesicles are used commonly to screen for interactions at
the transporter level, such systems may not be entirely predic-
tive of the interactions that may or may not occur in complex
cellular systems (eg, hepatocytes) or in vivo (Byrne et al., 2002;
Colombo et al., 2013; Xia et al., 2007). SCHH are a promising tool
to study drug disposition and hepatotoxicity (Marion et al., 2007;
Swift et al., 2010). Therefore, to further explore the interaction of
tolvaptan with hepatocellular bile acid transporters, the dispo-
sition of tolvaptan and bile acids was evaluated in SCHH.
Tolvaptan accumulation in SCHH was rapid and appeared to
consist of both passive and active uptake processes (Figure 5).
After a 10-min incubation with 15 lM tolvaptan, the total cellu-
lar concentration was 500 lM, assuming that all tolvaptan was
localized intracellularly. In SCHH, 30% of the tolvaptan dose
was metabolized over 10 min, with 1% and 10% representing
DM-4103 and DM-4107, respectively. The cellular concentrations
of DM-4103 and DM-4107 after a 10-min incubation with 15 lM
tolvaptan were 1.71 and 35.6 lM, respectively. Although DM-
4107 is formed preferentially compared with DM-4103 in about
a 10:1 ratio (DM-4107:DM4103) after 10 min in SCHH, DM-4103 is
the main circulating metabolite in vivo (Sorbera et al., 2002;
Tammara et al., 1999). This apparent discrepancy may be due to
differences in metabolite formation rates, ie, DM-4103 and DM-
4107 are downstream metabolites of tolvaptan (Tammara et al.,
1999).
Four bile acids (TCA, CDCA, TCDCA, and GCDCA) were used
as probes to determine the inhibitory potential of tolvaptan on
hepatocellular bile acid transport in SCHH. CDCA, TCDCA, and
GCDCA are among the most common circulating bile acids in
humans and alterations in their disposition have been impli-
cated in cholestatic liver injury (Greim et al., 1973; Ijare et al.,
2009; Perwaiz et al., 2001; Roda et al., 1998; Tagliacozzi et al.,
2003). Both the BEI and Clbiliary of TCA and CDCA in human
SCHH appeared to decrease (16% and 43% compared to control,
respectively, for TCA and 61% and 55% compared to control,
respectively, for CDCA) when incubated with tolvaptan (Table
3). The cellular accumulation of TCA was not altered by tolvap-
tan, indicating that cellular basolateral efflux may be able to
compensate for TCA accumulation even though TCA Clbiliary
was decreased; TCA Clbiliary is 3-fold greater than basolateral
clearance in SCHH (Yang et al., 2015). Similarly, both the BEI
and Clbiliary of CDCA in SCHH were modestly decreased (Table
3). Unlike TCA, CDCA appeared to accumulate intracellularly
when co-incubated with tolvaptan (increased by 1.3-fold rela-
tive to control) (Figure 6A). The cellular accumulation of
TCDCA and GCDCA also appeared to increase when co-
incubated with tolvaptan (increased by 1.68 - and 2.16-fold rel-
ative to control, respectively), which indicates the potential for
these bile acids to accumulate, possibly due to inhibition of
biliary and/or basolateral efflux (Figure 6B). The BEI for TCDCA
and GCDCA also appeared to be lower when co-incubated with
tolvaptan (Table 3). Inhibition of bile acid transport in SCHH is
consistent with the observations from the membrane vesicle
studies. These data support the hypothesis that accumulation
of tolvaptan in hepatocytes may play a role in the mecha-
nism(s) of DILI.
Although the cellular accumulation of bile acids such as
TCDCA has been shown to experimentally induce liver injury
in vivo (Sokol et al., 1998), the biological importance of such
changes in bile acid biliary clearance and hepatocyte accumula-
tion in humans is not well defined. In sandwich-cultured hepa-
tocytes, Marion et al. (2007) and Griffin et al. (2013) demonstrated
that some hepatotoxic drugs were associated with impaired bile
acid biliary clearance and/or increased cellular accumulation of
bile acids and subsequent toxicity, similar to the present find-
ings. Furthermore, this study examined bile acid disposition in
short-term incubations, which may be exacerbated in long-term
exposures as shown by the delayed presentation of bile acid-
mediated toxicity of troglitazone (Yang et al., 2014).
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As described earlier, inhibition of hepatic bile acid transport-
ers may not be the sole mechanism of DILI noted in the ADPKD
population. Alternative mechanisms of hepatotoxicity currently
are being explored. Wu et al. (2015) recently demonstrated that
tolvaptan induces in vitro cellular apoptosis in HepG2 cells,
potentially through several mechanisms including mitochon-
drial dysfunction. However, considering clinically relevant con-
centrations of tolvaptan and the fact that hepatotoxicity has
not been reported in non-ADPKD populations, the clinical rele-
vance of these studies remains uncertain. In addition to direct
drug-induced mitochondrial dysfunction and oxidative stress,
bile acids can cause hepatocellular damage by inducing swelling
and abnormal mitochondrial cristae, disruption of cellular
membranes, and generation of reactive oxygen species
(Billington et al., 1980; Philips et al., 1987; Sokol et al., 1993). As
described by Watkins et al. (2015), the signature pattern of hep-
atic events occurred after 3–4 months of treatment, and
resolved over a prolonged period of time following discontinua-
tion of tolvaptan. The signature pattern of hepatotoxicity sug-
gested an adaptive immune-mediated hepatic event, which
continues to be explored in patients. However, multiple mecha-
nisms of DILI cannot be ruled out including the inhibition of bile
acid transport, as shown here, and mitochondrial toxicity
(Feng et al., 2013). The results of studies focused on these alter-
native mechanism(s) will be reported subsequently. As noted at
the outset of this article, the purpose of the current investiga-
tion was to test the hypothesis that inhibition of human hepatic
bile acid transporters by tolvaptan and metabolites could play a
role in tolvaptan-associated DILI.
It has been suggested that inhibition of NTCP-mediated bile
acid uptake may provide some cellular protection from hepatic
accumulation of bile acids, such as shown with bosentan
(Leslie et al., 2007). However, the NTCP IC50 value for tolvaptan
(41.5 lM) was >2-fold higher than the dose concentration in
the SCHH studies, indicating that tolvaptan would have little
impact on TCA uptake in hepatocytes; this is consistent with
the data obtained in SCHH (Figure 6A). DM-4103 and DM-4107
concentrations in the media were negligible after a 10-min incu-
bation (data not shown); these metabolites likely had little
impact on TCA uptake in the present study. Based on Cmax con-
centrations achieved with therapeutic doses of tolvaptan, only
DM-4103 exhibited an I/IC50 >0.1 for NTCP (Table 1). However,
when taking into account the unbound fraction (assuming fu
1%, similar to that of tolvaptan, Shoaf et al., 2014), an interac-
tion at the level of NTCP would not be expected. Tolvaptan did
not appear to be a substrate of NTCP (Table 2). While NTCP is
considered the primary hepatic bile acid transporter in humans,
OATPs also transport endogenous anions including bile acids
and bilirubin (Cui et al., 2001; Meier et al., 1997; Tamai et al.,
2000). Although inhibition of OATPs is a concern for the interac-
tion of concomitantly administered drugs (Zhang, 2012), inhibi-
tion of OATPs has not been associated with DILI and thus, may
not be relevant to understanding bile acid-mediated toxicity/
disposition. Furthermore, OATP drug-drug interactions with tol-
vaptan have not been reported in humans (Bhatt et al., 2014).
In conclusion, results of this study demonstrate that tolvap-
tan and metabolites inhibited multiple human hepatic proteins
involved in bile acid transport (ie, NTCP, BSEP, MRP2, MRP3, and
MRP4). Impaired bile acid transport by tolvaptan and/or its
metabolites may negatively impact bile acid homeostasis,
which may explain, in part, the mechanism(s) behind liver
injury in tolvaptan-treated ADPKD patients. However, the fact
that liver injury has been observed only in patients with
ADPKD, and that no evidence of cholestasis (ie, no clinically
significant increases in alkaline phosphatase) was observed in
the ADPKD clinical trial (Torres et al., 2012), suggests that other
mechanisms may predispose this patient population to DILI.
Research into other genetic and nongenetic mechanisms of tol-
vaptan-induced DILI is on-going.
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